- Home
- DTIL
as 02-21-2025 4:00pm EST
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | DURHAM |
| Market Cap: | 43.3M | IPO Year: | 2019 |
| Target Price: | $37.67 | AVG Volume (30 days): | 123.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.45 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.61 - $19.43 | Next Earning Date: | 03-26-2025 |
| Revenue: | $75,096,000 | Revenue Growth: | 43.62% |
| Revenue Growth (this year): | 51.35% | Revenue Growth (next year): | -72.30% |
Stock Insider Trading Activity of Precision BioSciences Inc. (DTIL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Scimeca Dario | DTIL | General Counsel and Secretary | Jan 20 '25 | Sell | $4.79 | 8,928 | $42,765.12 | 24,353 | |
| SMITH J. JEFFERSON | DTIL | Chief Research Officer | Jan 20 '25 | Sell | $4.79 | 10,287 | $49,274.73 | 87,440 | |
| Amoroso Michael | DTIL | President and CEO | Jan 20 '25 | Sell | $4.67 | 36,838 | $172,033.46 | 107,087 | |
| Germano Geno J | DTIL | Director | Dec 30 '24 | Buy | $4.49 | 3,605 | $16,186.45 | 7,807 | |
| Kelly John Alexander | DTIL | Chief Financial Officer | Dec 27 '24 | Buy | $4.75 | 2,113 | $10,036.75 | 40,186 | |
| Buehler Kevin | DTIL | Director | Dec 27 '24 | Buy | $4.88 | 4,320 | $21,081.60 | 8,712 | |
| Brown Melinda | DTIL | Director | Dec 26 '24 | Buy | $4.55 | 3,016 | $13,722.80 | 7,218 |
Latest Precision BioSciences Inc. News
DTIL Breaking Stock News: Dive into DTIL Ticker-Specific Updates for Smart Investing
Argus Research
21 hours ago
Daily – Vickers Top Insider Picks for 02/21/2025
Clinical Trials Arena
2 days ago
Precision reports initial outcomes from Hepatitis B trial of PBGENE-HBV
Argus Research
2 days ago
Daily – Vickers Top Insider Picks for 02/20/2025
Benzinga
3 days ago
Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate
Business Wire
3 days ago
Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial
Argus Research
3 days ago
Daily – Vickers Top Insider Picks for 02/19/2025
Argus Research
4 days ago
Daily – Vickers Top Insider Picks for 02/18/2025
Business Wire
24 days ago
Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs
Compare DTIL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DTIL Precision BioSciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.